Welcome to our dedicated page for Clarivate Plc news (Ticker: $CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Clarivate Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Clarivate Plc's position in the market.
Clarivate reported first-quarter 2024 results with revenues of $621.2 million, a 1.3% decrease. The net loss attributable to ordinary shares was $93.8 million. Adjusted net income decreased by 20.9% to $103.5 million. The company reaffirmed its outlook for 2024.
Clarivate Plc (NYSE: CLVT) has introduced Epidemiology Intelligence™, a new solution that provides biopharma companies with epidemiology, incidence, and prevalence data, along with claims-based population insights, to enhance market sizing and patient population analysis. The tool aims to address limitations in traditional research methods, offering unique insights for accurate forecasting and identification of niche populations. The launch signifies Clarivate's commitment to delivering comprehensive solutions to the life sciences and healthcare industries.
Clarivate Plc (NYSE:CLVT) has launched the enhanced Cortellis CMC Intelligence solution with a post-approval variations module. This update allows pharmaceutical companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics. The module covers regulatory changes across 64 countries, reducing tracking time and increasing submission rates. Cortellis CMC Intelligence aims to simplify CMC regulatory dossier submissions, automate monitoring through alerts, and offer comprehensive lifecycle information for drugs and biologics.
Clarivate Plc declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares, payable on June 3, 2024. Each Preferred Share will convert into ordinary shares based on the VWAP of Clarivate's shares. The conversion rate depends on the VWAP value, with specific ratios based on price levels. Shareholders of record on May 15, 2024, will receive the dividend.
BioWorld by Clarivate explores the future of CAR T therapy in mainland China, focusing on the rapid pipeline growth, partnerships, clinical trials, and patient access challenges in cancer treatment. The report highlights the exponential growth of China's CAR T market, the blooming CAR T pipelines, and the difficulties in providing access to CAR T therapies due to high costs and reimbursement challenges.
